253 related articles for article (PubMed ID: 15606438)
21. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
23. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
Singh K; Dickinson L; Chaikan A; Back D; Fletcher C; Pozniak A; Moyle G; Nelson M; Gazzard B; Herath D; Boffito M
Clin Pharmacol Ther; 2008 Jun; 83(6):867-72. PubMed ID: 17898705
[TBL] [Abstract][Full Text] [Related]
25. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
[TBL] [Abstract][Full Text] [Related]
26. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
van der Lugt J; Autar RS; Ubolyam S; Garcia EF; Sankote J; Avihingsanon A; Chuenyam T; Cooper DA; Lange J; Phanuphak P; Wit F; Ruxrungtham K; Burger D;
J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
[TBL] [Abstract][Full Text] [Related]
29. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
30. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Dickinson L; Back D; Pozniak A; Khoo S; Boffito M
Ther Drug Monit; 2007 Jun; 29(3):361-7. PubMed ID: 17529895
[TBL] [Abstract][Full Text] [Related]
31. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
34. Saquinavir/low-dose ritonavir: its use in HIV infection.
Johnson M; Peters B
AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107
[TBL] [Abstract][Full Text] [Related]
35. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
[TBL] [Abstract][Full Text] [Related]
36. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
38. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
39. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
40. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
